stockrow
Friday 6 November 2026
Export INCR’s income statement to Excel — free account
InterCure Ltd.
INCR Healthcare Drug Manufacturers Specialty & Generic
InterCure Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $78.5 million, up 18.4% from fiscal 2024.
3.36
0.06
+1.82%
Follow INCR
Alert me
| Older periods | Mar '23 | Jun '23 | Jun '24 | Jun '25 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
2.04 | 16.05 | — | — |
P/S ratio |
0.14 | 3.22 | — | — | |
P/FCF ratio |
0.00 | 0.00 | — | — | |
P/Operating CF |
(1.17) | (26.04) | — | — | |
P/B ratio |
0.12 | 2.68 | — | — | |
Price to Tangible BV |
0.26 | 5.81 | — | — | |
EV/Sales |
0.31 | 3.20 | — | — | |
EV/EBITDA |
2.71 | 35.36 | — | — | |
EV/Operating CF |
(149.70) | (1,502.70) | — | — | |
EV/FCF |
(9.18) | (92.12) | — | — | |
Quick Ratio |
1.24 | 1.21 | 1.15 | 1.09 | |
Current Ratio |
1.83 | 1.90 | 1.78 | 1.85 | |
Net Debt/EBITDA |
8.07 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
22.15% | 12.52% | 9.32% | 15.51% | |
Debt/Equity |
0.37 | 0.20 | 0.15 | 0.27 | |
Asset Turnover |
0.51 | 0.51 | 0.00 | 0.00 | |
Operating CF/Net income |
(245.44) | 0.00 | — | 0.00 | |
Capex/Depreciation |
(0.22) | — | — | (0.38) | |
Interest Coverage |
1.04 | 0.00 | — | — | |
Research and Development Expense of Revenue |
0.14% | 0.10% | — | — | |
Selling, General and Administrative Expense of Revenue |
23.73% | 25.21% | — | — | |
Intangible Assets out of Total Assets |
0.32 | 0.34 | 0.30 | 0.30 | |
Share Based Compensation of Revenue |
1.28% | 0.00% | — | 0.00% | |
Graham Net Nets |
1.19 | 0.06 | — | — | |
Graham Number |
19.73 | 6.15 | — | — | |
Earnings Yield |
49.02% | 6.23% | — | — | |
Free Cash Flow Yield |
(23.90%) | (1.08%) | — | — | |
Revenue per Share |
3.65 | 0.60 | — | — | |
Operating CF per Share |
(1.74) | 0.00 | — | 0.00 | |
Capex per Share |
(0.02) | 0.00 | — | 0.00 | |
Free Cash Flow per Share |
(1.76) | 0.00 | — | 0.00 | |
Cash per Share |
3.98 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
17.30 | 0.00 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
17.30 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(15.07) | — | — | 2.50 | |
Working Capital |
54.53 | 51.17 | 43.42 | 48.10 | |
Capital Expenditures |
(0.19) | — | — | (0.91) | |
Net Current Asset Value |
20.76 | 22.01 | 24.68 | 15.23 | |
EV/EBIT |
3.65 | 36.60 | — | — | |
Capex to Sales |
0.01 | 0.00 | — | 0.00 | |
Price to Operating Income |
1.66 | 36.87 | — | — | |
| Other line items | |||||
Average Receivables |
31.71 | 29.32 | 46.37 | 43.29 | |
Average Payables |
27.07 | 26.86 | 25.54 | 31.48 | |
Average Inventory |
33.94 | 34.42 | 37.33 | 40.30 | |
Average Assets |
240.50 | 233.86 | 228.13 | 247.84 | |
Average Common Equity |
149.95 | 147.33 | 137.55 | 138.13 |
Columns are period end dates · fundamentals updated 26 Oct 2026